Detection of minimal residual disease methods and relationship to outcome in T-Lineage acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 32, Issue 1-2, 1998, Pages 65-75

  Dibenedetto, S P ^a   Lo Nigro, L ^a   Di Cataldo, A ^a   Schiliro G ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Minimal residual disease; Polymerase chain reaction; T cell acute lymphoblastic leukemia; T cell receptor genes

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; T LYMPHOCYTE RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; GENE REARRANGEMENT; HUMAN; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; REVIEW;

EID: 0032459592     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809059247     Document Type: Review

References (73)

1. Wasserman R, Galili N, Ito Y, Silver JH, Reichard BA, Shane S, Womer RB, Lange B, Rovera G (1992). Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. Journal of Clinical Oncology, 10, 1879-84.
2. Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R, Toogood I, Waters K, Tauro G, Ekert H. (1994). Outcome prediction in childhood acute lymphoblastic leukemia by molecular quantification of residual disease at the end of induction. Lancet, 343, 196.
3. Pullen DJ, Crist WM, Falletta JM, et al: A Pediatric Oncology Group classification protocol for acute lymphoblastic leukemia (AlinC 13): immunologic phenotypes and correlation with treated results: p 22 in Murphy S, Gilbert J (eds.) Leukemia Research: Advances in Biology and Treatment. Elsevier in Hollan. Experta Medica, New York 1983.
4. van Dongen JJM and Wolvers-Tettero ILM. (1991). Analysis of immunoglobulin and T-cell receptor genes. Part 1: Basic and technical aspects. Clinical Chimica Acta, 198, 1.
5. Davis MM and Bjorkmann PJ (1988). T-Cell antigen receptor genes and T-cell recognition. Nature, 334, 395.
6. La Faille JJ, DeCloux A, Bonneville M, Takagaki Y and Tonegawa S (1989). Junctional sequences of T-cell receptor γδ genes: implications of γ/δ T-cell lineages and for a novel intermediate of V-(D)-J joining. Cell, 59, 859-863.
7. Breit TM, Wolvers- Tettero ILM, Hahlen K, van Wering FR, van Dongen JJM (1991). Extensive Junctional diversity of γδ T-cell receptors expressed by T-cell acute lymphoblastic leukemias: implications for the detection of minimal residual disease. Leukemia, 5, 1076-1081.
8. Carrol AJ, Crist WM, Link MP, Amylon MD, Pullen DJ, Ragab AH, Buchanan GR, Wimmer RS, Vietti TJ (1990). The t(1;14) (p3.4; q1.1) translocation is non-random and restricted to T-cell acute lymphoblastic leukemia. A Pediatric Oncology Group Study. Blood, 76, 1220-24.
9. Brown L, Cheng J-T, Chen Q, Siciliano MJ, Crist W, Buchanan GR, Baer R (1990). Site-specific recombination of the TAL 1 gene is a common occurrence in human T-cell leukemia. EMBO Journal, 9, 3343-51.
10. Bernard O, Lecointe N, Jonveaux P, Soury M, Mauchauffe M, Berger R, Larson CJ, Mathie-Mahul D (1991). Two site-specific deletions and t(1;14) translocation restricted to human T-cell acute leukemias disrupt the 5′ part of the TAL 1 gene. Oncogene, 6, 1477-88.
11. Aplan PD, Lombardi PD, Reaman GH, Sather HR, Hammond GD, Krisch IR (1992). Involvement of the putative hematopoietic transcription factor SCL in T-cell acute lymphoblastic leukemia. Blood, 79, 1327-1333.
12. Jonsson OG, Kitchens RL, Baer RJ, Buchanan GR, Smith RG (1991). Rearrangements of the TAL-1 locus as clonal markers for T-cell acute lymphoblastic leukemia. Journal of Clinical Investigation, 87, 2029-34.
13. Breit TM, Beishuizen A, Ludwig WD, Mol EJ, Adriaasen HJ, Van Wering ER and van Dongen JJM (1993). Tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease. Leukemia, 7, 2004-11.
14. Bash RO, Crist W, Shuster JJ, Link MP, Amylon M, Pullen J, Carrol A, Buchanan GR, Smith G and Baer R (1993). Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to alterations at the TAL 1 locus: a Pediatric Oncology Group Study. Blood, 81, 2110-2117.
15. Pui CH, Behm FG, Crist WM (1993). Clinical and biological relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 82, 343-9.
16. van Dongen JJM and Wolvers-Tettero ILM (1991). Analysis of immunoglobulin and T-Cell receptor genes. Part II: Possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders. Clinical Chimica Acta 198, 93-108.
17. Breit TM, Wolvers-Tettero ILM, Beishuizen A, Verhoeven MAJ, Wering ER, van Dongen JJM (1993). Southern blot patterns, frequencies, and junctional diversity of T-cell receptor δ gene rearrangements in acute lymphoblastic leukemia. Blood 82, 3063-70.
18. Bonati A, Zanelli P, Savi M, Neri TM (1994). TcR β chain gene rearrangement and expression in human T-cell development and in leukemia. Leukemia, 8, 918-922.
19. Kneba M, Bolz I, Linke B and Hiddemann W (1995). Analysis of rearranged T-cell receptor β-chain genes by polymerase chain reaction (PCR) DNA sequencing and automated high-resolution PCR fragment analysis. Blood, 86, 3930-7.
20. Lefranc MP, Forster A and Rabbitts TH (1986). Rearrangement of two distinct T-cell gamma chain variable region genes in human DNA. Nature, 319, 420-2.
21. Lefranc MP, Forster A, Baer M, Stinson M and Rabbitts TH (1986). Diversity and rearrangement of the human T-cell rearranging gamma genes: nine germline variable genes belonging of two subgroups. Cell, 45, 237-24.
22. Chen Z, Font MP, Loiseau P, Bories C, Duparc L, Degos L, Lefranc MP and Sigaux F (1988). The Vγ locus: cloning of new segments and the study of Vγ rearrangements in neoplastic B and T cells. Blood, 72, 776-783.
23. Taylor JJ, Rowe D, Williamson IK, Christmas SE, Proctor SJ and Middleton PG (1991). Detection of T-cell receptor γ chain V gene rearrangements using the polymerase chain reaction: application of the study of clonal disease cells in acute lymphoblastic leukemia. Blood, 77, 1989-1995.
24. Steward GC, Goulden JN, Potter MN and Oakhill A (1993). The use of polymerase chain reaction to detect minimal residual disease in childhood acute lymphoblastic leukemia. European Journal of Cancer, 29, 1192-8.
25. Macintyre EA, d'Auriol L, Duparc N, Leverger G, Galibert F, Sigaux F (1990). Use of oligonucleotide probes directed against T-cell antigen receptor gamma delta Variable-(Diversity)-Joining junctional sequences as a general method for detecting minimal residual disease in acute lymphoblastic leukemias. Journal of Clinical Investigation, 86, 2125-2135.
26. Trainor KJ, Brisco MJ, Wan JH, Neoh S, Grist S, Morley AA (1991). Gene rearrangement in B- and T-lymphoproliferative disease detected by polymerase chain reaction. Blood, 78, 192-196.
27. Tycko B, Palmer JD, Link MP, Smith SD, Sklar J (1989). Polymerase chain reaction amplification of rearranged antigen receptor genes using junction-specific oligonucleotides: possible application for detection of minimal residual disease in acute lymphoblastic leukemia. Cancer Cell, 7, 47-52.
28. Veeklen H, Tycko B and Sklar J (1991). Sensitive detection of clonal antigen receptor gene rearrangements for the diagnosis and monitoring of lymphoid neoplasm by a polymerase chain reaction-mediated ribonuclease protection assay. Blood, 78, 1318-1326.
29. Norris MD, Kwan E, Haber M and Marshall CM (1995). Detection of evolving immunoglobulin heavy-chain gene rearrangements in acute lymphoblastic leukemia: a PCR-based assay employing overlapping DJH primers. Leukemia, 9, 1779-82.
30. Haber M, Kwan E, Zhu L, Marshall GM and Norris MD (1997). Sensitive non-radioactive PCR detection of clonal T-cell receptor-gamma gene rearrangements in childhood acute lymphoblastic leukaemia. British Journal of Haematology, 98, 995-8.
31. Biondi A, Champagne F, Rossi V, Giudici G, Cantù-Rajnoldi A, Masera G, Mantovani A, Mak TW and Minden MD (1989). T-cell receptor delta gene rearrangement in T-cell acute lymphoblastic leukemia. Blood, 73, 2133-2138.
32. Hata S, Brenner M., and Kragel M (1987). Identification of putative human T cell receptor δ complementary DNA clones. Science, 238, 678-682.
33. Takihara Y, Tkachuk D, Michalopoulos E, Champagne E, Reiman J, Minden M and Mak T (1988). Sequence and organization of the diversity, joining and constant region genes of the human T-cell δ chain gene. Proceeding National Academy of Science USA, 85, 6097-6101.
34. Satyanarayana K, Hata S, Devlin P, Roncarolo MG, De Vries E, Spits H, Strominger JL and Krangel MS (1988). Genomic organization of the human T-cell receptor α/δ locus. Proceeding National Academy of Science USA, 85, 8166-8170.
35. Biondi A, Di Celle PF, Rossi V, Casorati G, Matullo G, Giudici G, Foa R, Migone N (1990). High prevalence of Vδ2-(D)-Dδ3 or Dδ1/2-Dδ3 rearrangements in B-precursor acute lymphoblastic leukemias. Blood, 75, 1834-40.
36. Yokota S, Hansen-Hagge T, Bartram CR (1991). T-cell receptor δ gene recombination in common acute lymphoblastic leukemia: preferential use of Vδ2 and frequent involvement of the Ja cluster. Blood, 77, 141-8.
37. van Dongen JJM, Breit TM, Adriaansen HJ, Beishuizen A, Hooijkaas H (1992). Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia, 6, 47-59.
38. Neale GAM, Menarguez J, Kitchingman GR, Fitzgerald TJ, Koehler M, Mirro JJr, Goorha RM (1991). Detection of minimal residual disease in T-cell acute lymphoblastic leukemia using polymerase chain reaction predicts impending relapse. Blood, 78, 739-45.
39. Cave H, Guidai C, Rohrlich P, Defau MH, Broyart A, Lescoeur B, Rahimy C, Fenneteau O, Monplaisir N, d'Auriol L, Elion J, Vilmer E, Grandhamp B (1994). Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of Ig H and T-cell receptor genes. Blood, 83, 1892-97.
40. Seriu T, Hansen-Hagge TE, Erz DHR and Bartram CM (1995). Improved detection of minimal residual leukemia through modifications of polymerase chain reaction analyses based on clone-specific T-cell receptor junctions. Leukemia, 9, 316-320.
41. Taube T, Seeger K, Beyermann B, Hanel C, Duda S, Linderkamp C and Henze G (1997). Multiplex PCR for simultaneous detection of the most frequent T cell receptor-δ gene rearrangements in childhood ALL. Leukemia, 11, 1978-1982.
42. Dibenedetto SP, Lo Nigro L, Pine Mayer S, Rovera C and Schilirò G (1997). Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia. Blood, 90, 1226-1232.
43. Raimondi SC (1993). Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood, 81, 2237-2251.
44. Campana D and Pui CH (1995). Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood, 85, 1416-1434.
45. Biondi A, Yokota S, Hansen-Hagge TE, Rossi V, Giudici G, Maglia O, Basso G, Tell C, Masera G and Bartram CR (1992). Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse. Leukemia, 6, 282-288.
46. Kitchingman GR (1993). Immunoglobulin heavy chain gene VH-D junctional diversity at diagnosis in patients with acute lymphoblastic leukemia. Blood, 81, 775-783.
47. Steenbergen EJ, Verhagen OJHM, Leeuwen EF, Berg H, Borne AEGKr, School CE (1995). Frequent ongoing T-cell receptor rearrangements in childhood B-precursor acute lymphoblastic leukemia: Implications for monitoring minimal residual disease. Blood, 86, 692-706.
48. Ghali DW, Panzer S, Fischer S, Tirita AA, Haas OA, Kovar H, Gadner H, Grumayer ERP (1995). Heterogeneity of the T-cell receptor δ gene indicating subclone formation in acute precursor B-cell leukemias. Blood, 85, 2795-2801.
49. Beishuizen A, Verhoeven MJ, van Wering ER, Hahlen K, Hooijkaas and van Dongen JJM (1994). Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction. Blood, 83, 2238-2247.
50. Saiki RK, Gelfand DM, Stoffel S, Scharf SJ, Miguchi R, Horn GT, Mullis KB, Erlich HA (1988). Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science, 239, 487-492.
51. Baruchel A, Cayuela JM, Macintyre E, Berger R and Sigaux F (1995). Assessment of clonal evolution at Ig/TCR loci in acute lymphoblastic leukemia by single-strand conformation polymorphism studies and highly resolutive PCR-derived methods: implication for a general strategy of minimal residual disease detection. British Journal of Haematology, 90, 85-93.
52. Yamada M, Wasserman R, Lange B, Reichard BA, Womer RB, Rovera G (1990). Minimal residual disease in childhood B-lineage lymphocytic leukemia: persistence of leukemic cells during the first 18 months of treatment. New England Journal of Medicine, 323, 448-455.
53. Yokota S, Hansen-Hagge TE, Ludwig WD, Reiter A, Raghavackar A, Kleihauer E and Bartram CR (1991). Use of polymerase chain reaction to monitor minimal residual disease in acute lymphocytic leukemia patients. Blood, 77, 331-337.
54. Nizet Y, Van Daele S, Lewalle P, Vaerman JL, Philippe M, Vermylen C, Cornu G, Ferrant A, Michaux JL, Martial P (1993). Long term follow up of residual disease in ALL patients in complete remission using clonogenic IgH probes and the polymerase chain reaction. Blood, 82, 1618-1624.
55. Ito Y, Wasserman R, Galili N, Reichard B, Shane S, Lange B, Rovera G (1993). Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphocytic leukemia. Journal of Clinical Oncology, 11, 546-553.
56. Privitera E, Rivolta A, Ronchetti D, Mosna G, Giudici G, Biondi A (1996). Reverse transcriptase/polymerase chain reaction follow-up and minimal residual disease detection in t(1;19)-positive acute lymphoblastic leukaemia. British Journal of Haematology, 92, 653-658.
57. Cimino G, Elia L, Rivolta A, Rapanotti MC, Rossi V, Alimena G, Annino I., Canaani E, Lo Coco F, Biondi A (1996). Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL-1/AF-4 positive-acute lymphoblastic leukaemia. British Journal of Haematology, 92, 659-664.
58. Goulden N, Langlands K, Steward C, Kats F, Potter M, Chessels J and Oakhill A (1994). PCR assessment of bone marrow status in isolated extramedullary relapse of childhood B-precursor acute lymphoblastic leukaemia. British Journal of Haematology, 87, 282-5.
59. Kitchingman G.R (1994). Residual disease detection in multiple follow-up samples in children with acute lymphoblastic leukaemia. Leukemia, 8, 395-401.
60. Ito Y and Miyamura K (1994). Clinical significance of minimal residual disease in leukemia detected by polymerase chain reaction: is molecular remission a milestone for achieving a cure? Leukemia and Lymphoma, 16, 57-64.
61. Seriu T., Yokota S., Nakao M, Misawa S., Takaue Y, Koizumi S., Kawai S and Fujimoto T (1995). Prospecting monitoring of minimal residual disease during the course of chemotherapy in patients with lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for auto-transplantation. Leukemia, 9, 615-623.
62. Steenbergen EJ, Verhagen OJ, Van Leeuwen EF, Van den Berg H, Behrendt H, Slater RM, Van dem Borne AE and Van der School CE (1995). Prolonged persistence of PCR-detectable minimal residual disease after diagnosis of first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia, leukemia, 9, 1726-1734.
63. Hansen-Hagge TE, Yokota S, Bartram CR (1989). Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T cell receptor γ sequences. Blood, 74, 1762-8.
64. Reiter A, Schrappe M, Ludwig WD (1994). Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Result and conclusions of the multicenter trial ALL-BFM 86. Blood, 84, 3122-29.
65. Schorin M, Blattner S, Gelber R (1994). Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. Journal of Clinical Oncology, 12, 740-6.
66. Smith M, Arthur D, Camitta B, Carrol AJ, Crist W, Caynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui CH, Pullen J, Reaman G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R (1996). Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia Journal of Clinical Oncology, 14, 18-25.
67. Uckun FM, Sensel MG, Sun L, Steinherz PG, Trigg ME, Heerema NA, Sather HN, Reaman GH and Gaynon PS (1998). Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood, 91, 735-746.
68. Iolascon A, Faienza MF, Coppola B, Moretti A, Basso G, Amaru R, Viganò G and Biondi A (1997). Frequent clonal Ioss of heterozygosity (LOH) in the chromosomal region lp3.2 occurs in childhood T cell acute lymphoblastic leukemia (T-ALL) carrying rearrangements of the TAL-1 gene. Leukemia, 11, 359-363.
69. Van den Berg et al (1998). Favorable outcome after 1-year treatment of childhood T-cell lymphoma/T-cell acute lymphoblastic leukemia. Medical Pediatric Oncology, 30, 46-51.
70. Moonka D and Loy EY (1994). A consensus primer to amplify α and β chains of the human T cell receptor. Journal of Immunological Methods, 169, 41-46.
71. Roberts MW, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL and Zipf TF (1997). Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. New England Journal of Medicine, 336, 317-323.
72. Dibenedetto SP and Schilirò G (1997). Residual clones in childhood leukemia. New England Journal of Medicine, 337, 50.
73. Greaves M (1997). Silence of leukemic clone. New England Journal of Medicine, 336, 367-9.